Ophthalmology

INTRODUCTION

Τhe current modern lifestyle and especially the recently increased hours in front of a screen has led to a rapid increase in the incidence of dry eye disease. Dry eye is a multifactorial disease of the ocular surface that includes blepharitis, meibomian gland dysfunction, and chalazion. Essentially, spending long hours in front of a computer or a screen accelerates the evaporation process of the outer/lipid layer of the eye and leads to a dysfunction of the meibomian gland, which secretes this particular layer. In addition, dry eye is a symptom of other diseases such as Sjogren's syndrome. All the above have in common the disturbance of the balance in the tear film which is characterized by inflammation and is accompanied by eye symptoms. Existing treatment options focus on local relief by lubricating the cornea.

PRODUCT INFORMATION

Eyeaspis Dry Eye is a formulation, with ingredients that help to manage dry eyes and decongest the meibomian gland. Eyeaspis DE-Caps contains ingredients with proven anti-inflammatory action, as well as the substance of fatty acid in the meibomian gland to produce the right quality and quantity of the lipid layer (meibum).

Key components of the lipid layer with a strong anti-inflammatory effect are ω-3 fatty acids such as eicosapentaenoic acid (EPA), which is an essential fatty acid for the functions of the body and which the body is unable to synthesize on its own.

Eyeaspis Dry Eye has as its main ingredients EPA and DHA in re-esterified form of triglycerides and with anti-inflammatory action. In addition, vitamin D3 with 1000IU covers the basic needs of the body.

*Health claims according to (EU) Regulation 432/2012: DHA contributes to the maintenance of normal vision.

INTRODUCTION

Τhe current modern lifestyle and especially the recently increased hours in front of a screen have led to a rapid increase in the incidence of dry eye disease. Dry eye is a multifactorial disease of the ocular surface that includes blepharitis, meibomian gland dysfunction, and chalazion. Spending long hours in front of a computer or a screen accelerates the evaporation process of the outer/lipid layer of the eye and leads to a dysfunction of the meibomian gland, which secretes this particular layer. In addition, dry eye is a symptom of other diseases such as Sjogren's syndrome. All the above have in common the disturbance of the balance in the tear film which is characterized by inflammation and is accompanied by eye symptoms. Existing treatment options focus on local relief by lubricating the cornea.

PRODUCT INFORMATION

Eyeaspis DE-Caps is a product, which includes ingredients that help to manage dry eye disease and decongest the meibomian gland. The ingredients of Eyeaspis DE-Caps offer proven anti-inflammatory action, as well as the main substance of fatty acid in the meibomian gland to produce the right quality and quantity of the lipid layer (meibum).

Key components of the lipid layer with a strong anti-inflammatory effect are ω-3 fatty acids, such as eicosapentaenoic acid (EPA), which is an essential fatty acid for the functions of the body and which the body is unable to synthesize on its own.

Eyeaspis DE-Caps includes its main ingredient EPA in form of re-esterified triglycerides with anti-inflammatory action, as well as maqui berry extract, with antioxidant action (35% delphinidins). In addition, it contains Vitamin D3 and Vitamin B12 both of which cover the basic needs of the body.

INTRODUCTION

Glaucoma is one of the most common eye diseases affecting millions of people. It is characterized by  degeneration of the optic nerve leading to gradual and irreversible vision loss. Usually, fluid (aqueous humor) in the eye flows freely through the anterior chamber and exits through the drainage system (trabecular meshwork). The fluid is produced and drained from the eye forming the so-called intraocular pressure. When the aqueous humor cannot drain properly from the eye, it accumulates resulting in increased intraocular pressure.  The increased pressure is transferred to the back of the eye resulting in neurodegeneration of the optic nerve with gradual loss of vision. Oxidative stress is a key factor in the onset and progression of optic nerve degeneration. Treatments for glaucoma have so far focused on regulating intraocular pressure by trying to indirectly reduce the rate of progression of degeneration. However, it is necessary to protect the optic nerve from further degeneration.

PRODUCT INFORMATION

Optoaspis is a formulation with an innovative combination of ingredients, which contribute to the management of glaucoma and offer a quadruple mechanism of action. The product provides ingredients with an antioxidant mechanism to ganglion cells, which are sensitive to oxidation.

A key antioxidant component is astaxanthin, which is literally hundreds of times stronger than other antioxidant molecules. In addition, the product includes ingredients that increase blood microcirculation around the optic nerve, supplying the ganglion cells with nutrients. An active ingredient that contributes to blood microcirculation is the anthocyanins contained in Black currant extract.

The vitamins B9 & B12 contained in the product act on the metabolism of homocysteine* and cover the daily needs of glaucoma patients. Lastly, the innovation lies in the participation of the ingredients in the regulation of intraocular pressure.  This is achieved with Coleus Forskohlii extract with the active ingredient forskolin, which reduces the production of aqueous humor in the anterior part of the eye helping to reduce intraocular pressure.

*Health claims according to (EU) Regulation 432/2012: Vitamin B12 and folic acid contribute to the normal metabolism of homocysteine

INTRODUCTION

Diabetic retinopathy is the primary cause of blindness in 20-64 years old. Recent studies support that patients with diabetes after 10-15 years will develop diabetic retinopathy or have some degree of retinal damage.  The treatment options mainly focus on the last stages of the disease. Although it is a  health challenge, science is lagging in treatment options, especially, for the early stages of the disease where the excessive blood glucose damages the vessels walls and leads to gradually degeneration of the vessels increasing the oxidative stress and activating the inflammation.

In addition to diabetic retinopathy, patients with diabetes have an increased risk of developing vein occlusion. Although, in this particular case atherosclerosis is the most common cause. In vein occlusion, the retinal vein is blocked, preventing normal blood flow and leading to inflammation.

PRPDUCT INFORMATION

Retinoaspis is a formulation with ingredients that contribute to the better management of diabetic retinopathy and retinal vein occlusion.

Its components support the metabolism, structure and function of retinal cells. They offer a strong anti-inflammatory effect by promoting the production of anti-inflammatory cytokines.    A key anti-inflammatory component is docosahexaenoic acid (DHA)* which is a necessary component for the body’s function and cannot synthesize itself. Retinoaspis also includes components with antioxidant activity, thus providing the necessary antioxidant mechanism to the retina. Astaxanthin, contained in the product, is literally hundreds of times stronger than other antioxidant molecules.  Astaxanthin comes from the algae Haematococcus pluvialis and is a natural carotenoid. Retinoaspis includes vitamin B12, which covers the body's vitamin needs, regulates homocysteine ​​levels* and also provides anti-inflammatory effect.

*Health claims according to (EU) Regulation 432/2012: DHA contributes to the maintenance of normal vision. Vitamin B12 contributes to normal homocysteine metabolism.

Coming Soon!